Digital Health Innovation in Cardiovascular Diseases (Executive Briefing)

Digital Health Innovation in Cardiovascular Diseases is experiencing a surge of interest as evidenced by the recent significant increase in partnerships in 2023 compared to the same quarter in 2022. Among the ventures with solutions for Clinical Trials, they are leading in clinical evidence with over half of them having an Evidence Signal greater than 40. This is a promising sign for the future of Cardiovascular Disease treatment as it suggests that these ventures are producing effective solutions that are backed by strong clinical evidence. However, the total venture capital funding for Cardiovascular solutions in Digital Health decreased by 31% from 2021 to 2022, totaling $3.4B in 2022. This could be due to a number of factors such as market conditions or investor sentiment. Additionally, the exit activity for Cardiovascular ventures was low in 2022 which followed on in the first quarter of 2023. This could indicate that investors are taking a more cautious approach towards Cardiovascular ventures, or that there are simply fewer opportunities for acquisition. It’s worth noting that from 2020 to 2023, Patient Solutions was one of the top 3 largest clusters for newly incorporated ventures that focused primarily on Cardiovascular Diseases. This suggests that there is a growing focus on patient-centered solutions in this area of healthcare, which could lead to more effective and personalized treatments for patients with Cardiovascular Diseases. HealthTech Alpha, a Galen Growth proprietary solution, powers this report!